Drug Trial Radar · NCT06841679
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
778
Planned (sponsor's estimate)
Start
Aug 28, 2025
Primary completion
Sep 1, 2030
Study completion Sep 1, 2030
Sponsor
- Lead sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.
Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
Utidelone CapsuleDrug
UTD2 40 mg/m2/d, po, qd, day 1-5, q3w
Utidelone CapsuleDrug
50 mg/m2/d, po, qd, day 1-5, q3w
Utidelone CapsuleDrug
60 mg/m2/d, po, qd, day 1-5, q3w
Fluoropyrimidine- and Platinum-containing TherapyDrug
CAPOX: Capecitabine 1700 mg/m2/d, po, bid, d1-14,q3w, Oxaliplatin 130 mg/m2, iv, d1, q3w. After completing 6 times (18 weeks) of oxaliplatin treatment, the investigator may decide whether to continue oxaliplatin treatment for up to 8 times (24 weeks) based on the participant's benefits and safety. FOLFOX: Oxaliplatin 85 mg/m2, iv, d1, q2w. Folinic Acid 400 mg/m2, iv, d1, q2w, 5-FU 400 mg/m2 IV bolus d1 then 5-FU 2400 mg/m2 IV infusion over 46 to 48 hours, q2w. After completing 9 times (18 weeks) of treatment with oxaliplatin combined with folinic acid and 5-FU, the investigator may decide whether to continue FOLFOX treatment for up to 12 times (24 weeks) based on the participant's benefits and safety.
OxaliplatinDrug
130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles
Utidelone CapsuleDrug
UTD2 po, on d1-5, q3w (dose decided after the phase II)
PD-1 inhibitorDrug
Whether to combine a PD-1 inhibitor will depend on the locally approved indications for the PD-1 inhibitor. If the participant's condition meets the locally approved indications for PD-1 inhibitors, the investigator may determine, in accordance with clinical guidelines, that the participant is eligible to receive treatment with UTD2 combined with fluoropyrimidine- and platinum-containing therapy, with or without a PD-1 inhibitor. If a PD-1 inhibitor is administered in combination, tislelizumab (200 mg), or pembrolizumab (200 mg), or nivolumab (360 mg), iv, day1, q3w. Alternatively, the investigator may select the dosage and administration cycle of other locally approved PD-1 inhibitors in accordance with the locally approved package inserts. The PD-1 inhibitor will be given up to 2 years.
CapecitabineDrug
Capecitabine 1700 mg/m2/d po, bid, d1-14,q3w
CapecitabineDrug
Capecitabine, 2000 mg/m2/d, po, bid, d1-14, q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of UTD2 and capecitabine in combination with oxaliplatin in Phase IITime frame: From Day 1 to Day 21
- Overall Survival (OS)Time frame: 12 months
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Bioresearch Partner
Hialeah, Florida · Not yet recruiting
AnYang Tumor Hospital
Anyang, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Jinan Municipal Central Hospital
Jinan, China · Recruiting
Shandong First Medical University Affiliated Tumor Hospital
Jinan, China · Recruiting
Liaoning Cancer Hospital
Shenyang, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.